Phase I-B trial of the radiosensitizer: Etanidazole (SR-2508) with radiosurgery for the treatment of recurrent previously irradiated primary brain tumors or brain metastases (RTOG Study 95-02)

被引：12

作者：

Drzymala, R. E. ^{[1
]}

Wasserman, T. H. ^{[1
]}

Won, M. ^{[2
]}

Shaw, E. ^{[3
]}

Cmelak, A. J. ^{[4
]}

Loeffler, J. ^{[5
]}

Souhami, L. ^{[6
]}

机构：

[1] Washington Univ, Med Ctr, St Louis, MO USA

[2] Radiat Therapy Oncol Grp, Philadelphia, PA USA

[3] Wake Forest Univ, Winston Salem, NC 27109 USA

[4] Vanderbilt Univ, Nashville, TN USA

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

[6] McGill Univ, Montreal, PQ, Canada

来源：

RADIOTHERAPY AND ONCOLOGY | 2008年 / 87卷 / 01期

关键词：

etanidazole; SR-2508; radiosurgery; brain tumors;

D O I：

10.1016/j.radonc.2008.02.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

RTOG 95-02 assessed patient tolerance to hypoxic cell radiosensitizer, etanidazole (SR-2508), combined with radiosurgery. Patients had primary or metastatic brain tumors and previously localized or whole brain irradiation. The toxicity is reported in three groups of patients according to the tumor size. Etanidazole doses of 12 g/m(2) combined with radiosurgery were well tolerated. (C) 2008 Elsevier Ireland Ltd. All rights reserved.

引用

页码：89 / 92

页数：4

共 24 条

[1] STEREOTAXIC RADIOSURGICAL TREATMENT OF BRAIN METASTASES [J].

ADLER, JR ;

COX, RS ;

KAPLAN, I ;

MARTIN, DP .

JOURNAL OF NEUROSURGERY, 1992, 76 (03) :444-449

[2] Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial [J].

Andrews, DW ;

Scott, CB ;

Sperduto, PW ;

Flanders, AE ;

Gaspar, LE ;

Schell, MC ;

Werner-Wasik, M ;

Demas, W ;

Ryu, J ;

Bahary, JP ;

Souhami, L ;

Rotman, M ;

Mehta, MP ;

Curran, WJ .

LANCET, 2004, 363 (9422) :1665-1672

[3]

Boyd TS, 1999, ONCOLOGY-NY, V13, P1397

[4] 1ST ANALYSIS ON TUMOR-REGRESSION FOR THE EUROPEAN RANDOMIZED TRIAL OF ETANIDAZOLE COMBINED WITH RADIOTHERAPY IN HEAD AND NECK CARCINOMAS [J].

CHASSAGNE, D ;

CHARREAU, I ;

SANCHOGARNIER, H ;

ESCHWEGE, F ;

MALAISE, EP .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (03) :581-584

[5] FINAL REPORT OF THE PHASE-I TRIAL OF THE HYPOXIC CELL RADIOSENSITIZER SR-2508 (ETANIDAZOLE) RADIATION-THERAPY ONCOLOGY GROUP-83-03 [J].

COLEMAN, CN ;

WASSERMAN, TH ;

URTASUN, RC ;

HALSEY, J ;

NOLL, L ;

HANCOCK, S ;

PHILLIPS, TL .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (02) :389-393

[6]

COX JD, 1995, INT J RADIAT ONCOL, V32, P567

[7] On the interpretation of x(2) from contingency tables, and the calculation of P [J].

Fisher, RA .

JOURNAL OF THE ROYAL STATISTICAL SOCIETY, 1922, 85 :87-94

[8] Motexafin gadolinium: a novel radiosensitizer for brain tumors [J].

Forouzannia, Afshin ;

Richards, Gregory M. ;

Khuntia, Deepak ;

Mehta, Minesh P. .

EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (06) :785-794

[9] RTOG NUMBER-89-06 - A PHASE-I STUDY TO EVALUATE INTRAOPERATIVE, RADIATION-THERAPY AND THE HYPOXIC CELL SENSITIZER ETANIDAZOLE IN LOCALLY ADVANCED MALIGNANCIES [J].

HALBERG, FE ;

COSMATIS, D ;

GUNDERSON, LL ;

NOYES, RD ;

HANKS, GR ;

BUSWELL, L ;

NAGORNEY, DM ;

COLEMAN, CN .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1994, 28 (01) :201-206

[10] DISTRIBUTION OF ETANIDZOLE INTO HUMAN BRAIN-TUMORS - IMPLICATIONS FOR TREATING HIGH-GRADE GLIOMAS [J].

HURWITZ, SJ ;

COLEMAN, CN ;

RIESE, N ;

LOEFFLER, JS ;

ALEXANDER, E ;

BUSWELL, L ;

NEBEN, TY ;

SHARGEL, L ;

KRAMER, RA .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 22 (03) :573-576

← 1 2 3 →